ProMetic, MacoPharma Successfully Complete P-Capt Clinical Studies

Armen Hareyan's picture

The successful completion of two human clinical studies performed on volunteers using the P-Capt prion reduction filter for red cell concentrates has been announced by ProMetic, MacoPharma. The clinical studies evaluated the effect of the filter on units of red cell concentrate collected from human volunteers, to ensure that the use of the filter had no negative effect on the red blood cells themselves. Data demonstrated no negative impact.

"These studies represent the first use of the P-Capt prion filter in humans and the results demonstrate that not only is the product effective in reducing the risk of transmission of variant Creutzfeldt-Jakob disease ("vCJD") by blood transfusion but also there is no impact of the treatment on the blood itself," stated Mr. Christophe Vinzia, MacoPharma's Director of Business Development. "This represents a major milestone and we anticipate the positive results will encourage early adoption of the product in the UK and Ireland".


Please, click to subscribe to our Youtube Channel to be notified about upcoming health and food tips.